Fig. 4From: A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studyProportion of patients with ACR/EULAR remission in the intent-to-treat population, with nonresponder imputation approach. a ACR/EULAR remission by Boolean-based criterion. b ACR/EULAR remission by index-based criterion (SDAI). p value was calculated using Fisher’s exact test. ACR American College of Rheumatology, EULAR European League Against Rheumatism, RP reference product (i.e., reference infliximab), SDAI Simplified Disease Activity IndexBack to article page